Literature DB >> 11895960

Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine.

Mitchell B Cohen1, Ralph A Giannella, Judy Bean, David N Taylor, Susan Parker, Amy Hoeper, Stephen Wowk, Jennifer Hawkins, Sims K Kochi, Gilbert Schiff, Kevin P Killeen.   

Abstract

Peru-15 is a live attenuated oral vaccine derived from a Vibrio cholerae O1 El Tor Inaba strain by a series of deletions and modifications, including deletion of the entire CT genetic element. Peru-15 is also a stable, motility-defective strain and is unable to recombine with homologous DNA. We wished to determine whether a single oral dose of Peru-15 was safe and immunogenic and whether it would provide significant protection against moderate and severe diarrhea in a randomized, double-blind, placebo-controlled human volunteer cholera challenge model. A total of 59 volunteers were randomly allocated to groups to receive either 2 x 10(8) CFU of reconstituted, lyophilized Peru-15 vaccine diluted in CeraVacx buffer or placebo (CeraVacx buffer alone). Approximately 3 months after vaccination, 36 of these volunteers were challenged with approximately 10(5) CFU of virulent V. cholerae O1 El Tor Inaba strain N16961, prepared from a standardized frozen inoculum. Among vaccinees, 98% showed at least a fourfold increase in vibriocidal antibody titers. After challenge, 5 (42%) of the 12 placebo recipients and none (0%) of the 24 vaccinees had moderate or severe diarrhea (> or = 3,000 g of diarrheal stool) (P = 0.002; protective efficacy, 100%; lower one-sided 95% confidence limit, 75%). A total of 7 (58%) of the 12 placebo recipients and 1 (4%) of the 24 vaccinees had any diarrhea (P < 0.001; protective efficacy, 93%; lower one-sided 95% confidence limit, 62%). The total number of diarrheal stools, weight of diarrheal stools, incidence of fever, and peak stool V. cholerae excretion among vaccinees were all significantly lower than in placebo recipients. Peru-15 is a well-tolerated and immunogenic oral cholera vaccine that affords protective efficacy against life-threatening cholera diarrhea in a human volunteer challenge model. This vaccine may therefore be a safe and effective tool to prevent cholera in travelers and is a strong candidate for further evaluation to prevent cholera in an area where cholera is endemic.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11895960      PMCID: PMC127885          DOI: 10.1128/IAI.70.4.1965-1970.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  16 in total

1.  Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area.

Authors:  E E Richie; N H Punjabi; Y Y Sidharta; K K Peetosutan; M M Sukandar; S S Wasserman; M M Lesmana; F F Wangsasaputra; S S Pandam; M M Levine; P P O'Hanley; S J Cryz; C H Simanjuntak
Journal:  Vaccine       Date:  2000-05-08       Impact factor: 3.641

2.  ABO blood groups and cholera: new observations on specificity of risk and modification of vaccine efficacy.

Authors:  J D Clemens; D A Sack; J R Harris; J Chakraborty; M R Khan; S Huda; F Ahmed; J Gomes; M R Rao; A M Svennerholm
Journal:  J Infect Dis       Date:  1989-04       Impact factor: 5.226

3.  Duration of serum antitoxin response following Vibrio cholerae infection in North Americans: relevance for seroepidemiology.

Authors:  M M Levine; C R Young; T P Hughes; S O'Donnell; R E Black; M L Clements; R Robins-Browne; Y L Lim
Journal:  Am J Epidemiol       Date:  1981-09       Impact factor: 4.897

4.  Comparison of alternative buffers for use with a new live oral cholera vaccine, Peru-15, in outpatient volunteers.

Authors:  D A Sack; J Shimko; R B Sack; J G Gomes; K MacLeod; D O'Sullivan; D Spriggs
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

5.  Predisposition for cholera of individuals with O blood group. Possible evolutionary significance.

Authors:  R I Glass; J Holmgren; C E Haley; M R Khan; A M Svennerholm; B J Stoll; K M Belayet Hossain; R E Black; M Yunus; D Barua
Journal:  Am J Epidemiol       Date:  1985-06       Impact factor: 4.897

6.  Magnitude, kinetics, and duration of vibriocidal antibody responses in North Americans after ingestion of Vibrio cholerae.

Authors:  M L Clements; M M Levine; C R Young; R E Black; Y L Lim; R M Robins-Browne; J P Craig
Journal:  J Infect Dis       Date:  1982-04       Impact factor: 5.226

7.  Development of a live, oral, attenuated vaccine against El Tor cholera.

Authors:  D N Taylor; K P Killeen; D C Hack; J R Kenner; T S Coster; D T Beattie; J Ezzell; T Hyman; A Trofa; M H Sjogren
Journal:  J Infect Dis       Date:  1994-12       Impact factor: 5.226

8.  Peru-15, an improved live attenuated oral vaccine candidate for Vibrio cholerae O1.

Authors:  J R Kenner; T S Coster; D N Taylor; A F Trofa; M Barrera-Oro; T Hyman; J M Adams; D T Beattie; K P Killeen; D R Spriggs
Journal:  J Infect Dis       Date:  1995-10       Impact factor: 5.226

9.  Serological studies in cholera. 2. The vibriocidal antibody response of cholera patients determined by a microtechnique.

Authors:  A S Benenson; A Saad; W H Mosley
Journal:  Bull World Health Organ       Date:  1968       Impact factor: 9.408

10.  Enzyme-linked immunosorbent assay to measure antibodies to purified heat-labile enterotoxins from human and porcine strains of Escherichia coli and to cholera toxin: application in serodiagnosis and seroepidemiology.

Authors:  M M Levine; C R Young; R E Black; Y Takeda; R A Finkelstein
Journal:  J Clin Microbiol       Date:  1985-02       Impact factor: 5.948

View more
  25 in total

Review 1.  Enteric pathogens as vaccine vectors for foreign antigen delivery.

Authors:  Camille N Kotton; Elizabeth L Hohmann
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

Review 2.  New-generation vaccines against cholera.

Authors:  John Clemens; Sunheang Shin; Dipika Sur; G Balakrish Nair; Jan Holmgren
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-11-08       Impact factor: 46.802

3.  Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR, prepared from new master and working cell banks.

Authors:  Wilbur H Chen; Richard N Greenberg; Marcela F Pasetti; Sofie Livio; Michael Lock; Marc Gurwith; Myron M Levine
Journal:  Clin Vaccine Immunol       Date:  2013-10-30

Review 4.  Cholera.

Authors:  Jason B Harris; Regina C LaRocque; Firdausi Qadri; Edward T Ryan; Stephen B Calderwood
Journal:  Lancet       Date:  2012-06-30       Impact factor: 79.321

5.  TcpF is a soluble colonization factor and protective antigen secreted by El Tor and classical O1 and O139 Vibrio cholerae serogroups.

Authors:  Thomas J Kirn; Ronald K Taylor
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

6.  Vaccines against gastroenteritis, current progress and challenges.

Authors:  Hyesuk Seo; Qiangde Duan; Weiping Zhang
Journal:  Gut Microbes       Date:  2020-06-18

7.  The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers.

Authors:  Luis García; Manuel Díaz Jidy; Hilda García; Boris L Rodríguez; Roberto Fernández; Gemma Año; Bárbara Cedré; Tania Valmaseda; Edith Suzarte; Margarita Ramírez; Yadira Pino; Javier Campos; Jorge Menéndez; Rodrigo Valera; Daniel González; Irma González; Oliver Pérez; Teresita Serrano; Miriam Lastre; Fernando Miralles; Judith Del Campo; Jorge Luis Maestre; José Luis Pérez; Arturo Talavera; Antonio Pérez; Karen Marrero; Talena Ledón; Rafael Fando
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

8.  Refinement of a human challenge model for evaluation of enterotoxigenic Escherichia coli vaccines.

Authors:  Clayton Harro; Subhra Chakraborty; Andrea Feller; Barbara DeNearing; Alicia Cage; Malathi Ram; Anna Lundgren; Ann-Mari Svennerholm; August L Bourgeois; Richard I Walker; David A Sack
Journal:  Clin Vaccine Immunol       Date:  2011-08-18

9.  Induction of interleukin-8 in T84 cells by Vibrio cholerae.

Authors:  Xin Zhou; Da Q Gao; Jane Michalski; Jorge A Benitez; James B Kaper
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

Review 10.  Exploiting cholera vaccines as a versatile antigen delivery platform.

Authors:  Anisia J Silva; Francis O Eko; Jorge A Benitez
Journal:  Biotechnol Lett       Date:  2007-11-16       Impact factor: 2.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.